Physician profile
Robert Mccallum
NPI 1134264427
$9,984.59
in general payments reported to CMS, 2019-2025
38 companies · $2,520 in 2025
The $2,520 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,119 · 2020: $325 · 2021: $468 · 2022: $1,238 · 2023: $2,532 · 2024: $1,783 · 2025: $2,520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,780 · Education: $54.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,780.13 |
| Education | $54.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,101.38 | 2019-2025 | |
| Janssen Biotech, INC. | $1,403.36 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $880.54 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $873.27 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $712.95 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Celgene Corporation | $544.80 | 2022-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $385.03 | 2024-2025 | Zenpep, Vowst |
| Genzyme Corporation | $373.75 | 2022-2025 | |
| Ardelyx, INC. | $278.04 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $226.67 | 2022-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $201.94 | 2024-2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $201.37 | 2019-2025 | Ocaliva |
| Medtronic, INC. | $195.64 | 2023 | Signia, Pillcam |
| Lilly USA, LLC | $178.68 | 2025 | Omvoh |
| Merck Sharp & Dohme LLC | $152.67 | 2022-2024 | Dificid, Zinplava |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $127.61 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2023 | Zeposia |
| Janssen Scientific Affairs, LLC | $124.98 | 2019 | |
| Madrigal Pharmaceuticals | $112.71 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $99.27 | 2020-2024 | Linzess |
| Celltrion USA INC. | $96.12 | 2023-2025 | Yuflyma, Vegzelma |
| Mylan Institutional INC. | $64.84 | 2023 | Hulio |
| Evoke Pharma, INC. | $62.32 | 2024-2025 | |
| Nestle Healthcare Nutrition INC. | $59.78 | 2021-2023 | |
| Novo Nordisk INC | $53.63 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $48.20 | 2022-2023 | Rebyota |
| Redhill Biopharma INC. | $46.97 | 2021-2022 | |
| Braintree Laboratories, INC. | $46.50 | 2021-2025 | Suflave, Sutab |
| Ethicon US, LLC | $36.23 | 2019-2022 | |
| Ucb, INC. | $25.76 | 2019 | |
| Amgen INC. | $25.70 | 2022 | |
| Biocon Biologics INC | $23.56 | 2025 | Yesintek |
| Alexion Pharmaceuticals, INC. | $19.93 | 2019 | |
| Qol Medical, LLC | $18.17 | 2019 | |
| Shionogi INC | $16.81 | 2019 | |
| Organon LLC | $14.32 | 2024 | |
| Shire North American Group INC | $13.61 | 2019 | |
| Allergan, INC. | $12.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mccallum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.